Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Aptinyx | Vintage Vibes

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…

Benzinga · Aug 25, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022

Benzinga · Aug 16, 2022

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga · Aug 12, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Expert Ratings for Aptinyx

Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings:

Benzinga · May 19, 2022

Recap: Aptinyx Q1 Earnings

Aptinyx (NASDAQ:APTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Aptinyx beat estimated earnings by 3.33%, reporting an EPS of $-0.29 versus an estimate of $-0.3.

Benzinga · May 12, 2022

Expert Ratings for Aptinyx

Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings:

Benzinga · Apr 21, 2022

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Apr 7, 2022

Read news from The Economist, FT, and more,
with one subscription

Aptinyx: Q4 Earnings Insights

Aptinyx (NASDAQ:APTX) reported its Q4 earnings results on Wednesday, March 23, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Aptinyx beat estimated earnings by 17.14%, reporting an EPS of $-0.29 versus an estimate of $-0.35.

Benzinga · Mar 23, 2022

Earnings Preview For Aptinyx

Aptinyx (NASDAQ:APTX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that Aptinyx will report an earnings per share (EPS) of $-0.35.

Benzinga · Mar 22, 2022

Coverage From

Benzinga

Organisations

US Food and Drug Administration

63 stories

Seagen

60 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.